Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Neutral

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Coherus BioSciences, Inc. (CHRS)

Biological Products, (no Disgnostic Substances)

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600
REDWOOD CITY, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/06/2014

Market Cap

153,159,210

Shares Outstanding

111,360,000

Weighted SO

111,364,152

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

ASMB --.--%

SPRO --.--%

ACHL --.--%

TIL --.--%

NLTX --.--%

NXTC --.--%

NUVB --.--%

CTMX --.--%

BOLT --.--%

Beta

0.6000

Last Div

0.0000

Range

1.22-5.465

Chg

-0.2150

Avg Vol

1635985

Mkt Cap

153159210

Exch

NASDAQ

Country

US

Phone

650 649 3530

DCF Diff

3.5401

DCF

11.8801

Div Yield

0.0000

P/S

0.4971

EV Multiple

-1.9122

P/FV

-1.8225

Div Yield %

0.0000

P/E

-5.2244

PEG

-0.1309

Payout

0.0000

Current Ratio

1.2050

Quick Ratio

1.0708

Cash Ratio

0.3439

DSO

371.4368

DIO

123.3232

Op Cycle

494.7601

DPO

152.3993

CCC

342.3608

Gross Margin

0.4029

Op Margin

-0.5082

Pretax Margin

-0.0965

Net Margin

-0.0952

Eff Tax Rate

0.3206

ROA

-0.0435

ROE

0.2381

ROCE

-0.7392

NI/EBT

0.9872

EBT/EBIT

0.1898

EBIT/Rev

-0.5082

Debt Ratio

0.4359

D/E

-3.4976

LT Debt/Cap

1.4084

Total Debt/Cap

1.4004

Int Coverage

-25.5340

CF/Debt

-0.1845

Equity Multi

-8.0237

Rec Turnover

0.9827

Pay Turnover

2.3950

Inv Turnover

2.9597

FA Turnover

92.4217

Asset Turnover

0.4566

OCF/Share

-0.4726

FCF/Share

-0.4729

Cash/Share

1.3869

OCF/Sales

-0.1761

FCF/OCF

1.0006

CF Coverage

-0.1845

ST Coverage

-13.1785

CapEx Coverage

-1596.1471

Div&CapEx Cov

-1596.1471

P/BV

-1.8225

P/B

-1.8225

P/S

0.4971

P/E

-5.2244

P/FCF

-2.8205

P/OCF

-2.8245

P/CF

-2.8245

PEG

-0.1309

P/S

0.4971

EV Multiple

-1.9122

P/FV

-1.8225

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Jan 22, 15:41 Why Coherus Biosciences Popped Today GlobeNewswire Inc. Jan 22, 01:15 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal GlobeNewswire Inc. Jan 22, 01:15 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal GlobeNewswire Inc. Jan 02, 08:29 Coherus Announces U.S. Launch of LOQTORZIâ„¢ The Motley Fool Dec 28, 15:45 Why Coherus BioSciences Stock Jumped Today The Motley Fool Dec 28, 15:45 Why Coherus BioSciences Stock Jumped Today MarketWatch Dec 27, 10:00 2024 could turn into a 'trader's market.' Here's how this strategist says you can make the most of that. Benzinga Dec 27, 07:35 S&P 500, Nasdaq Set For Wobbly Open As Santa Claus Rally Fades: Analyst Sees Final Trading Sessions As 'Last Great Buying Opportunity' Benzinga Dec 26, 16:30 Coherus BioSciences Stock Is Soaring After-Hours - Here's Why Benzinga Dec 26, 16:30 Coherus BioSciences Stock Is Soaring After-Hours - Here's Why Benzinga Dec 26, 16:30 Coherus BioSciences Stock Is Soaring After-Hours - Here's Why Benzinga Dec 26, 16:30 Coherus BioSciences Stock Is Soaring After-Hours - Here's Why Benzinga Dec 26, 16:30 Coherus BioSciences Stock Is Soaring After-Hours - Here's Why Benzinga Dec 26, 16:30 Coherus BioSciences Stock Is Soaring After-Hours - Here's Why Benzinga Dec 26, 16:30 Coherus BioSciences Stock Is Soaring After-Hours - Here's Why The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

Revenue Product Segmentation